Skip to main content

Breast Cancer

Breast Cancer

Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer

Breast Cancer

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

Breast Cancer, Antibody–Drug Conjugates

Emerging Immunotherapy Combination Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody–Drug Conjugates, and Bispecific Antibodies

Breast Cancer

Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: An Overview of Clinical Management and Potential Toxicities

Breast Cancer

SASCIA Phase 3 Trial Evaluating Sacituzumab Govitecan in Patients with Primary HER2-Negative Breast Cancer with High Relapse Risk

Breast Cancer

Trastuzumab Deruxtecan Granted Breakthrough Therapy Designation in United States for Patients with HER2-Positive Metastatic Breast Cancer Treated with ≥1 Previous Anti-HER2–Based Regimens

Breast Cancer, Antibody–Drug Conjugates

New Antibody–Drug Conjugates in Breast Cancer

Breast Cancer

Advancements in Targeted Therapy and Immunotherapy for Human Breast Cancer

Breast Cancer

Latest Updates on Targeted Therapy in HR-Positive and HER2-Negative Breast Cancer

Breast Cancer, CDK4/6 Inhibitors

Resistance Mechanisms to CDK4/6 Blockade in Advanced HR-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities

Page 4 of 12
Results 31 - 40 of 117